Literature DB >> 25625482

Autoreactivity to isoforms of glycoprotein 2 in inflammatory bowel disease.

Dirk Roggenbuck1, Nadja Röber2, Dimitrios P Bogdanos3, Alexander Goihl4, Dirk Reinhold4, Karsten Conrad2, Martin W Laass5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25625482     DOI： 10.1016/j.cca.2015.01.018

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


× No keyword cloud information.
  4 in total

1.  Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.

Authors:  Frauke Degenhardt; Andrea Dirmeier; Rocio Lopez; Sylvia Lang; Claudia Kunst; Dirk Roggenbuck; Dirk Reinhold; Silke Szymczak; Gerhard Rogler; Frank Klebl; Andre Franke; Florian Rieder
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

2.  Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.

Authors:  Martin W Laass; Nadja Röber; Ursula Range; Lydia Noß; Dirk Roggenbuck; Karsten Conrad
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

3.  Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.

Authors:  Mandy Sowa; Rafał Kolenda; Daniel C Baumgart; Johann Pratschke; Maria Papp; Tamas Tornai; Jaroslaw Suchanski; Dimitrios P Bogdanos; Maria G Mytilinaiou; Jutta Hammermann; Martin W Laass; Karsten Conrad; Christoph Schramm; Andre Franke; Dirk Roggenbuck; Peter Schierack
Journal:  Front Immunol       Date:  2018-08-28       Impact factor: 7.561

4.  Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ewa Wunsch; Gary L Norman; Malgorzata Milkiewicz; Marcin Krawczyk; Chelsea Bentow; Zakera Shums; Michael Mahler; Steffi Lopens; Dirk Reinhold; Andre Franke; Christoph Schramm; Dirk Roggenbuck; Piotr Milkiewicz
Journal:  Aliment Pharmacol Ther       Date:  2020-11-07       Impact factor: 8.171
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.